

UNIVERSITI TEKNOLOGI MARA

**EVALUATION OF VIROLOGICAL
AND IMMUNOLOGICAL RESPONSE,
AND INCIDENCE OF ZIDOVUDINE-INDUCED
ANAEMIA AMONG INNOVATOR AND
GENERIC ZIDOVUDINE/LAMIVUDINE**

NOR MAZNI MOHAMAD TAMYES

Dissertation submitted in partial fulfilment of the requirements
for the degree of
Master of Clinical Pharmacy

Faculty of Pharmacy

February 2016

AUTHOR'S DECLARATION

I declare that the work in this dissertation was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated or acknowledged as referenced work. This writing has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I hereby acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name : Nor Mazni binti Mohamad Tamyas
Student ID : 2014450534
Department : Clinical Pharmacy
Faculty : Pharmacy
Dissertation : Evaluation of Immunological and Virological Response, and
Incidence of Zidovudine-induced Anaemia among Innovator and
Generic Zidovudine/Lamivudine

Signature :

Date : February 2016

ABSTRACT

Zidovudine/Lamivudine (AZT/3TC) are commonly used in HAART regimen as the backbone NRTI for first-line therapy in developing countries. A generic combination tablet of AZT/3TC is currently used in all government hospitals in Malaysia. Studies comparing safety and efficacy of generic AZT/3TC are very limited. Thus, a retrospective observational cohort study was conducted to evaluate virological and immunological response, and anaemia incidence among patients treated with AZT/3TC. A total of 109 samples were recruited, with 65 samples initiated innovator and 44 generic. Virological and immunological response in both cohort were similar. Although viral load suppression to undetectable level (< 50 copies/ml) in generic group was slightly earlier as compared to innovator (median: seven months vs. eight months), this was not statistically significant ($p = 0.550$). Similarly, mean difference in terms of increment of CD4 cell count post 12 months therapy and median duration to achieve CD4 count >350 cells/ μ l were not statistically significant ($p = 0.505$ and $p = 0.190$). Incidence of Zidovudine-induced anaemia were found in 10.8% ($n = 7$) in innovator and 15.9% ($n = 7$) in generic cohort, with median time to develop anaemia was two and three months respectively ($p = 0.169$). In conclusion, our findings demonstrated similar clinical outcomes in patients treated with either innovator or generic formulation of AZT/3TC in terms of virological and immunological response. The risk of developing Zidovudine-induced anaemia was also similar in both groups. Therefore, it is justifiable to use generic AZT/3TC as the backbone NRTI in HAART regimen.

TABLE OF CONTENTS

	Page
AUTHOR'S DECLARATION	iii
ABSTRACT	iii
ACKNOWLEDGEMENT	iv
TABLE OF CONTENTS	v
LIST OF TABLES	ix
LIST OF FIGURES	xi
LIST OF ABBREVIATIONS/SYMBOLS/NOMENCLATURES	xii
CHAPTER ONE: INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statement	3
1.3 Rationale of The Study	4
1.4 Research Objectives	4
1.4.1 Primary Objectives	4
1.4.2 Secondary Objectives	5
CHAPTER TWO: LITERATURE REVIEW	6
2.1 Highly Active Antiretroviral Therapy (HAART)	6
2.2 Monitoring Parameters	10
2.2.1 Virological Response (Viral Load)	11
2.2.2 Immunological Response (CD4 Cell Count Level)	11
2.3 Generic Antiretroviral Medications	13
2.4 Zidovudine/Lamivudine	16
2.5 Anaemia in Retroviral Disease Patients	19

2.5.1 Zidovudine-induced Anaemia	20
2.6 Conclusion	25
CHAPTER THREE: RESEARCH METHODOLOGY	26
3.1 Study Design	26
3.2 Study Period	26
3.3 Sample Size Determination	27
3.4 Patient Selection	27
3.4.1 Inclusion and Exclusion Criteria	28
3.5 Data Collection	29
3.6 Outcome Assessment and Monitoring	31
3.6.1 Definitions Used in The Study	32
3.7 Statistical Analysis	32
3.8 Research Registration and Ethical Approval	33
CHAPTER FOUR: RESULTS	34
4.1 Demographic and Clinical Characteristics	34
4.2 Evaluation of Virological Success between Innovator and Generic AZT/3TC	39
4.2.1 Comparing Mean Difference of Viral Load Level at Six Months between Innovator and Generic AZT/3TC	39
4.2.2 Comparing Mean Difference of Virological Response between Innovator and Generic AZT/3TC	40
4.2.3 Association between Virological Response with Innovator Generic AZT/3TC	40
4.3 Evaluation of Immunological Success between Innovator and Generic and Generic AZT/3TC	42